Complete Omics Inc., a clinical proteomics and multi-omics technology company, announced the successful completion of its Series A financing, exclusively led by Qiming Venture Partners. The investment represents a major step forward in scaling the company’s technology platforms and accelerating the clinical translation of next-generation proteomics.
Founded in 2019, Complete Omics is focused on building the measurement infrastructure for the human proteome, enabling large-scale and highly reproducible detection of disease-associated proteins in clinical samples such as plasma and tissues. The company has developed a portfolio of patented technologies designed to overcome long-standing challenges in clinical proteomics, enabling stable, high-throughput, and quantitative measurement of thousands of proteins relevant to human disease.
Scaling Clinical Proteomics for Precision Medicine
The Series A investment will support the continued expansion of the company’s core technology platforms, including:
-
Complete360®, an ultra-deep clinical proteomics platform capable of measuring thousands of proteins across complex clinical samples
-
Valid-NEO®, a highly sensitive targeted proteomics platform designed for the detection and quantitative validation of tumor neoantigens from extremely small tumor specimens
Together, these platforms enable comprehensive molecular characterization across a wide range of diseases and provide a foundation for applications including early disease detection, therapeutic target discovery, and precision medicine development.
A Rapidly Emerging Field
In recent years, proteomics has become one of the most rapidly growing areas in life sciences, with global companies such as Olink and SomaLogic bringing large-scale protein measurement technologies to the market. The growing demand for accurate and reproducible protein measurements—particularly in clinical samples—has created a major opportunity for technologies capable of delivering deeper molecular insights into human disease.
Complete Omics is addressing this challenge by developing technologies that significantly expand the depth and quantitative reliability of proteomic measurements, helping bridge the long-standing gap between proteomics research and real-world clinical applications.
A Platform for Next-Generation Molecular Medicine
The investment from Qiming Venture Partners will enable Complete Omics to accelerate research and development, expand clinical studies, and strengthen collaborations with leading pharmaceutical companies and academic institutions worldwide.
Dr. Qing Wang, Founder and CEO of Complete Omics, commented:
“We are grateful for the strong support and recognition from Qiming Venture Partners. This investment reflects confidence in our team’s long-term vision and technology platform. Our mission is to advance clinical proteomics into real-world medical applications and build a new molecular measurement layer for next-generation medicine.”
With this investment, Complete Omics continues to expand its role in advancing the clinical applications of proteomics and multi-omics technologies, with the goal of becoming a global leader in molecular diagnostics and precision medicine platforms.
